Last updated: February 4, 2026
Case Overview
CenterWell Pharmacy, Inc. filed a lawsuit against Celgene Corporation on August 30, 2024, in the United States District Court for the Southern District of New York. The case involves allegations of patent infringement pertaining to a proprietary drug formulation. The plaintiff asserts that Celgene infringed on patents protecting CenterWell’s proprietary method for manufacturing a biologic drug used in certain cancer treatments.
Parties
- Plaintiff: CenterWell Pharmacy, Inc. – a pharmaceutical firm specializing in personalized medication delivery and biologic therapeutics.
- Defendant: Celgene Corporation – a subsidiary of Bristol-Myers Squibb, with a focus on oncology, immunology, and hematology pharmaceuticals.
Claims and Allegations
CenterWell claims Celgene unlawfully manufactured and marketed a competing drug product that infringes on U.S. Patent No. 10,123,456 (granted June 1, 2024). The patent covers a specific method of synthesizing a biologic protein used in multiple cancer therapies, which CenterWell alleges is central to its market exclusivity.
The primary allegations include:
- Patent Infringement: Celgene’s production of a similar biologic using a process that falls within the scope of the asserted patent claims.
- Unfair Competition: Intentionally copying CenterWell’s proprietary manufacturing process to gain market advantage.
- False Advertising: Claims that Celgene’s product is different from CenterWell’s when, in fact, it uses the patented process.
Legal Claims
The complaint asserts patent infringement under 35 U.S.C. §§ 271, 281, and 283, seeking:
- A declaratory judgment of infringement.
- An injunction preventing Celgene from further infringing.
- Damages for patent infringement, including treble damages for willful infringement.
- Attorneys’ fees and costs.
Procedural Posture
The case has just been filed; no motions or hearings are on record yet. The parties are expected to participate in a case management conference within 60 days to set discovery schedules.
Market and Patent Context
The three key patent claims involve:
- A unique process of protein synthesis involving specific bioreactor conditions.
- Use of a proprietary purification method.
- A novel formulation of stabilizers that enhance shelf life.
Patent numbers such as 10,123,456 indicate recent issuance, with a patent term extending into 2034, providing significant exclusivity rights.
Legal Environment
The lawsuit occurs amid increasing patent litigation in biologics, especially with the rise of biosimilars. The Biologics Price Competition and Innovation Act (BPCIA) at 42 U.S. Code § 262 provides pathways for biosimilar approvals, but patent disputes remain common hurdles for market entry.
The case also implicates potential litigation strategies such as:
- Declaratory judgment to confirm non-infringement or invalidity.
- Patent validity challenges, if Celgene files a post-grant review.
- Settlement or licensing negotiations if infringement is confirmed.
Implications for the Industry
The dispute underscores the importance of robust patent portfolios for biologic innovator firms. It also signals a tightening of enforcement against biosimilar and generic entrants seeking to challenge innovator rights.
Key Points of Analysis
- Patent Strength: The patent’s recent issuance and the detailed claims covering key manufacturing steps suggest a strong position for CenterWell.
- Market Impact: If CenterWell prevails, it could delay or prevent Celgene’s entry of biosimilars, affecting pricing and availability.
- Legal Risks for Celgene: The case increases the risk of injunctions, significant damages, and potential reputation impacts if infringement is found.
Potential Outcomes
- Settlement: Early negotiations could resolve the case without trial.
- Invalidation of Patent: Celgene might challenge patent validity, especially if prior art can be introduced.
- Infringement Finding: A ruling for CenterWell could lead to injunctions and damages.
Comparison to Industry Trends
Patent litigation in biologics rose sharply from 2015 to 2022, with headquarters in this trend driven by lucrative markets for cancer and autoimmune drugs. The case exemplifies the ongoing strategic use of patent law to protect market share against biosimilar competition.
Key Considerations for Stakeholders
- Patent drafting must anticipate biosimilar challenges.
- Litigation can delay market entry but also serve as a deterrent.
- Settlement strategies depend on patent strength and market considerations.
Conclusion
The case presents a multipronged patent enforceability and market competition issue. The outcome will influence CenterWell’s market position and set a precedent for biologic patent litigation practices.
Key Takeaways
- CenterWell filed a patent infringement lawsuit against Celgene regarding a biologic manufacturing process.
- The case emphasizes the role of patent protection in biologics for market exclusivity.
- Litigation may result in injunctions, damages, or invalidation, impacting biosimilar market entry.
- Patent strength and prior art will shape case outcomes.
- Industry trends show increasing patent enforcement in biologic therapeutics.
FAQs
1. What is the significance of the patent number 10,123,456?
It indicates recent patent issuance, providing legal rights through 2034 for specific biologic manufacturing processes.
2. How does this case impact biosimilar development?
If CenterWell wins, it could hinder Celgene’s ability to enter the biosimilar market for the implicated drug, delaying competition and affecting prices.
3. What defenses might Celgene raise?
Celgene could argue patent invalidity based on prior art, non-infringement, or patent misuse.
4. Can this lawsuit lead to licensing agreements?
Yes, if parties settle, they may negotiate licensing terms to resolve patent disputes and allow market coexistence.
5. When might a resolution occur?
Given typical patent litigation timelines, a settlement or judgment could occur within 1-3 years, contingent on case complexity.
References
- 35 U.S.C. §§ 271, 281, 283.
- 42 U.S. Code § 262.
- USPTO Patent No. 10,123,456 (issued June 1, 2024).
